The UK Myeloma Society advocates on behalf of healthcare professionals to improve access to treatments for our patients. The society nominates clinical experts that are involved in all stages of the NICE appraisals process, providing feedback on draft scoping documents, attending workshops and appraisal meetings. We are keen to involve patients and patient and carer groups in consultation processes and work closely with Myeloma UK to achieve this. A summary of recent NICE appraisals where we have advocated on behalf of the clinical community are listed below.
We also advocate in other areas such as working towards stream-lines treatment pathways and ensuring state of the art diagnostics for all patients in the UK.
The Pathway Optimisation Group, through horizon scanning and demand signalling, aims to improve the pathway for myeloma. As a unmet-need-driven UKMS initiative in collaboration with Myeloma UK, which is complimentary to classical NICE appraisals, the group aims to optimise use of therapeutics but also diagnostics to improve patient outcomes.
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable
Technology appraisal guidance [ID4014] Expected publication 25 October 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897) June 2023
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783) April 2023
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA870) February 2023
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763) February 2022
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680) March 2021
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA587) June 2019
Carfilzomib for previously treated multiple myeloma (TA695) April 2021
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
- Available via CDF
- NICE appraisal ongoing
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
- Following on from advice received from the company the timelines for this appraisal remain to be confirmed.
- Further information regarding the scheduling of this appraisal will be available in due course.
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
- Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]
- Following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course.
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
- On hold
Based on information available on NICE website (https://www.nice.org.uk/search?q=myeloma&gst=In%20development)
Click here to visit our Annual Report page.
Find out more about the UK Myeloma Society.